February 6, 2025
TOPLINE: Type I interferon (IFN) score may effectively predict disease progression in limited cutaneous systemic sclerosis (lcSSc), with patients having a high IFN activity presenting worse […]
February 4, 2025
TOPLINE: ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with glucocorticoid-dependent polymyalgia rheumatica […]
February 4, 2025
TOPLINE: Extra X chromosomes significantly increase the risk for systemic lupus erythematosus (SLE) and Sjögren disease, with the prevalence of these conditions being higher among patients […]
February 3, 2025
TOPLINE: Over one third of patients with giant cell arteritis exhibit vascular inflammation even after receiving treatment with tocilizumab and glucocorticoids for at least 6 months, […]
February 3, 2025
The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 […]
January 30, 2025
Biosimilars are often promoted as cost-saving alternatives to their reference medications. Designed to provide comparable therapeutic efficacy at a reduced price, they have the potential to […]
January 30, 2025
TOPLINE: Discontinuing adalimumab increases relapse rates in patients with juvenile idiopathic arthritis (JIA)–associated uveitis. However, patients can regain inflammation control after resuming the treatment. METHODOLOGY: Researchers […]
January 30, 2025
TOPLINE: The positive predictive value (PPV) of myositis antibodies for diagnosing myositis and its related conditions differs by individual antibody type. Greater diagnostic accuracy is associated […]
January 27, 2025
TOPLINE: Large language models (LLMs) perform differently in answering rheumatology questions, with ChatGPT-4 demonstrating higher accuracy and quality than Gemini Advanced and Claude 3 Opus. However, […]